. 2019 Mar 6;24(5):918. doi: 10.3390/molecules24050918

Table 2.

Overview of the putative hair-relevant therapeutic potential of cutaneous cannabinoid signaling.

Disease	Intervention	Level of Evidence	References
Unwanted hair growth (hirsutism, hypertrichosis)	Certain CB₁ agonists	Ex vivo (organ culture) data	[130]
Unwanted hair growth (hirsutism, hypertrichosis)	TRPV1, TRPV3 and TRPV4 activators	Ex vivo (organ culture) data	[135,136,137,138]
Unwanted hair loss (different non-immune alopecia forms)	Certain CB₁ antagonists/inverse agonists	Ex vivo (organ culture) and in vivo (mouse) data	[130,134]
Unwanted hair loss (different non-immune alopecia forms)	TRPV1, TRPV3 and TRPV4 antagonists	Ex vivo (organ culture) data	[135,136,137,138]
Alopecia areata	Elevation of the eCB-tone; certain CB₁ agonists, low doses of CBD ¹	Hypothesis based on the available data	[31,130,140,146,147,148,149,150,151,152,154]

¹ Note that well-controlled studies proving the efficiency of the indicated interventions are missing; however, in light of the available data, cannabinoid signaling might exert beneficial effects in alopecia areata, therefore it deserves systematic experimental exploration.